Table 1.
Correlation of MIR‐378 hypomethylation with clinical features in MDS
| Clinical parameters | MIR‐378 hypomethylation | |||
|---|---|---|---|---|
| No (n = 75) | Yes (n = 20) | Total (n = 95) | p | |
| Age (years)a | 60 (20–86) | 63.5 (27–85) | 60 (20–86) | .560 |
| Sex (male/female) | 39/36 | 16/4 | 55/40 | .040 |
| WBC (×109/L)a | 2.8 (0.9–26.6) | 2.4 (1.3–19.5) | 2.7 (0.9–26.6) | .204 |
| HB (g/L)a | 68 (26–128) | 58 (29–104) | 63.5 (26–118) | .088 |
| PLT (×109/L)a | 63 (0–754) | 60 (9–1176) | 61.5 (0–1176) | .964 |
| Cytogenetics | .607 | |||
| Good | 54 | 15 | 69 | |
| Intermediate | 9 | 1 | 10 | |
| Poor | 5 | 3 | 8 | |
| No data | 7 | 1 | 8 | |
| WHO classifications | .486 | |||
| RARS | 8 | 4 | 12 | |
| RCMD (RS) | 32 | 5 | 37 | |
| 5q‐ | 2 | 0 | 2 | |
| RAEB‐1 | 16 | 4 | 20 | |
| RAEB‐2 | 16 | 7 | 23 | |
| MDS‐U | 1 | 0 | 1 | |
| FAB classifications | .222 | |||
| RA | 32 | 7 | 39 | |
| RARS | 15 | 2 | 17 | |
| RAEB | 26 | 11 | 37 | |
| RAEBt | 2 | 0 | 2 | |
| IPSS | .541 | |||
| Low | 5 | 3 | 8 | |
| Int‐1 | 45 | 9 | 54 | |
| Int‐2 | 13 | 4 | 17 | |
| High | 8 | 2 | 10 | |
| No data | 4 | 2 | 6 | |
| Gene mutations | ||||
| U2AF1 (+/−) | 5/66 | 2/15 | 7/81 | .616 |
| IDH1/2 (+/−) | 4/68 | 0/17 | 4/85 | 1.000 |
| DNMT3A (+/−) | 2/70 | 1/16 | 3/86 | .475 |
| SF3B1 (+/−) | 5/66 | 1/16 | 6/82 | 1.000 |
Abbreviations: FAB, French‐American‐British; HB, hemoglobin; IPSS, International Prognostic Scoring System; MDS, myelodysplastic syndrome; PLT, platelet count; RA, refractory anemia; RAEB, RA with excess of blasts; RARS, RA with ringed sideroblasts; RCMD, refractory cytopenia with multilineage dysplasia; RCMD‐RS, RCMD with ringed sideroblasts; WBC, white blood cells; WHO, World Health Organization.
a
Median (range).